Early Detection of Ulcerative Colitis-associated Colorectal Cancer

Overview

Journal Gastroenterol Rep (Oxf)

Specialty Gastroenterology

Date 2018 May 22

PMID 29780595

Citations 29

Authors

Yu Zhen

Chengxin Luo

Hu Zhang

Affiliations

Soon will be listed here.

Abstract

Colitis-associated colorectal cancer (CACC) is one of the most serious complications of inflammatory bowel disease (IBD), particularly in ulcerative colitis (UC); it accounts for approximately 15% of all-causes mortality among IBD patients. Because CACC shows a worse prognosis and higher mortality than sporadic colorectal cancer, early detection is critical. Colonoscopy is primarily recommended for surveillance and several advanced endoscopic imaging techniques are emerging. In addition, recent studies have reported on attempts to develop clinically relevant biomarkers for surveillance using various biosamples, which may become high-performance screening tools in the future, so the best approach and technique for cancer surveillance in long-standing UC patients remain under debate. This review gives a comprehensive description and summary about what progress has been made in terms of early CACC detection.

Citing Articles

Gegen Qinlian Decoction Attenuates Colitis-Associated Colorectal Cancer via Suppressing TLR4 Signaling Pathway Based on Network Pharmacology and In Vivo/In Vitro Experimental Validation.

Xu Y, Cai Q, Zhao C, Zhang W, Xu X, Lin H Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861077 PMC: 11768880. DOI: 10.3390/ph18010012.

TYK2 Protein Expression and Its Potential as a Tissue-Based Biomarker for the Diagnosis of Colorectal Cancer.

Zadka L, Ustaszewski A, Glatzel-Plucinska N, Rusak A, Laczmanska I, Ratajczak-Wielgomas K Cancers (Basel). 2024; 16(21).

PMID: 39518103 PMC: 11545102. DOI: 10.3390/cancers16213665.

Identification and Validation of Biomarkers to Predict Early Diagnosis of Inflammatory Bowel Disease and Its Progression to Colorectal Cancer.

Khan F, Abdulla N, du Plessis T, Karlsson K, Barrow P, Bebington B Biochem Genet. 2024; .

PMID: 39325241 DOI: 10.1007/s10528-024-10917-z.

An inflammation-related subtype classification for analyzing tumor microenvironment and clinical prognosis in colorectal cancer.

Pei J, Gao Y, Wu A Front Immunol. 2024; 15:1369726.

PMID: 38742117 PMC: 11089903. DOI: 10.3389/fimmu.2024.1369726.

Microbial metabolites are involved in tumorigenesis and development by regulating immune responses.

Liu J, Tian R, Sun C, Guo Y, Dong L, Li Y Front Immunol. 2024; 14:1290414.

PMID: 38169949 PMC: 10758836. DOI: 10.3389/fimmu.2023.1290414.

References

Sjoqvist U, Hertervig E, Nilsson A, Duan R, Ost A, Tribukait B . Chronic colitis is associated with a reduction of mucosal alkaline sphingomyelinase activity. Inflamm Bowel Dis. 2002; 8(4):258-63. DOI: 10.1097/00054725-200207000-00004. View

Koon H, Zhao D, Na X, Moyer M, Pothoulakis C . Metalloproteinases and transforming growth factor-alpha mediate substance P-induced mitogen-activated protein kinase activation and proliferation in human colonocytes. J Biol Chem. 2004; 279(44):45519-27. DOI: 10.1074/jbc.M408523200. View

Eaden J, Abrams K, Mayberry J . The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001; 48(4):526-35. PMC: 1728259. DOI: 10.1136/gut.48.4.526. View

So J, Tang W, Leung W, Li M, Lo F, Wong M . Cancer Risk in 2621 Chinese Patients with Inflammatory Bowel Disease: A Population-based Cohort Study. Inflamm Bowel Dis. 2017; 23(11):2061-2068. DOI: 10.1097/MIB.0000000000001240. View

Khor B, Gardet A, Xavier R . Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011; 474(7351):307-17. PMC: 3204665. DOI: 10.1038/nature10209. View

Kiesslich R, Goetz M, Lammersdorf K, Schneider C, Burg J, Stolte M . Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. Gastroenterology. 2007; 132(3):874-82. DOI: 10.1053/j.gastro.2007.01.048. View

Gerecke C, Scholtka B, Lowenstein Y, Fait I, Gottschalk U, Rogoll D . Hypermethylation of ITGA4, TFPI2 and VIMENTIN promoters is increased in inflamed colon tissue: putative risk markers for colitis-associated cancer. J Cancer Res Clin Oncol. 2015; 141(12):2097-107. DOI: 10.1007/s00432-015-1972-8. View

Patel M, Verma A, Aslam I, Pringle H, Singh B . Novel plasma microRNA biomarkers for the identification of colitis-associated carcinoma. Lancet. 2015; 385 Suppl 1:S78. DOI: 10.1016/S0140-6736(15)60393-2. View

Isidro R, Cruz M, Isidro A, Baez A, Arroyo A, Gonzalez-Marques W . Immunohistochemical expression of SP-NK-1R-EGFR pathway and VDR in colonic inflammation and neoplasia. World J Gastroenterol. 2015; 21(6):1749-58. PMC: 4323450. DOI: 10.3748/wjg.v21.i6.1749. View

10.

Meyer R, Freitag-Wolf S, Blindow S, Buning J, Habermann J . Combining aneuploidy and dysplasia for colitis' cancer risk assessment outperforms current surveillance efficiency: a meta-analysis. Int J Colorectal Dis. 2016; 32(2):171-182. DOI: 10.1007/s00384-016-2684-5. View

11.

Ananthakrishnan A, Cagan A, Cai T, Gainer V, Shaw S, Churchill S . Colonoscopy is associated with a reduced risk for colon cancer and mortality in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014; 13(2):322-329.e1. PMC: 4297589. DOI: 10.1016/j.cgh.2014.07.018. View

12.

Harpaz N, Taboada S, Ko H, Yu J, Yang Q, Xu H . Expression of MACC1 and MET in inflammatory bowel disease-associated colonic neoplasia. Inflamm Bowel Dis. 2014; 20(4):703-11. DOI: 10.1097/01.MIB.0000442679.39804.48. View

13.

Jess T, Simonsen J, Jorgensen K, Pedersen B, Nielsen N, Frisch M . Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology. 2012; 143(2):375-81.e1. DOI: 10.1053/j.gastro.2012.04.016. View

14.

Jess T, Rungoe C, Peyrin-Biroulet L . Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2012; 10(6):639-45. DOI: 10.1016/j.cgh.2012.01.010. View

15.

Farraye F, Odze R, Eaden J, Itzkowitz S . AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010; 138(2):746-74, 774.e1-4. DOI: 10.1053/j.gastro.2009.12.035. View

16.

Zackular J, Rogers M, Ruffin 4th M, Schloss P . The human gut microbiome as a screening tool for colorectal cancer. Cancer Prev Res (Phila). 2014; 7(11):1112-21. PMC: 4221363. DOI: 10.1158/1940-6207.CAPR-14-0129. View

17.

Yusuf F, Ilyas S, Damanik H, Fatchiyah F . Microbiota Composition, HSP70 and Caspase-3 Expression as Marker for Colorectal Cancer Patients in Aceh, Indonesia. Acta Med Indones. 2017; 48(4):289-299. View

18.

Brentnall T, Crispin D, Rabinovitch P, Haggitt R, RUBIN C, Stevens A . Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology. 1994; 107(2):369-78. DOI: 10.1016/0016-5085(94)90161-9. View

19.

East J . Colonoscopic Cancer Surveillance in Inflammatory Bowel Disease: What's New Beyond Random Biopsy?. Clin Endosc. 2012; 45(3):274-7. PMC: 3429750. DOI: 10.5946/ce.2012.45.3.274. View

20.

Soetikno R, Subramanian V, Kaltenbach T, Rouse R, Sanduleanu S, Suzuki N . The detection of nonpolypoid (flat and depressed) colorectal neoplasms in patients with inflammatory bowel disease. Gastroenterology. 2013; 144(7):1349-52, 1352.e1-6. DOI: 10.1053/j.gastro.2013.04.008. View